Narrowing a drug's clinical claims is the ultimate escape hatch for applications doomed by trial design disputes.
When contentious statistical disagreements or negative advisory votes threaten to kill a drug's regulatory review, developers can salvage the application by stripping out disputed endpoints and refining the proposed indication.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
After facing a major regulatory rejection over heart function efficacy data, Capricor narrowed its proposed clinical indication to a skeletal muscle endpoint to save the application.
Capricor amended its BLA to target a narrower upper-limb skeletal muscle claim rather than risk an outright rejection of its heart-focused data.
Capricor's application faced a devastating rejection due to a fundamental dispute with regulators over which statistical analysis plan should govern the clinical data.